Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2013
IR News
2013 IR News
RSS
IR News
12.09.2013
Notice on the Establishment of Subsidiary in Singapore
12.06.2013
European marketing authorization application for Ikervis has been filed to the EMA for the treatment of Dry Eye Disease
11.29.2013
Santen to Support People in the Philippines Affected by Typhoon Haiyan through Donations
11.25.2013
Santen Launches Alesion® 0.05% Ophthalmic Solution for Allergic Conjunctivitis Treatment in Japan
11.22.2013
Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
10.17.2013
Announcing the Opening of the Ho Chi Minh Representative Office
10.10.2013
Santen Announces the Launch of TAPROS MINI Ophthalmic Solution 0.0015% for Glaucoma and Ocular Hypertension
09.20.2013
Santen Announces Approval of Alesion® 0.05% Ophthalmic Solution for Allergic conjunctivitis Treatment in Japan
09.20.2013
Santen Announced Approval for TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension
09.02.2013
Notice on Details of the Rights to Subscribe for New Shares(Stock Options as Stock-Linked Remuneration)
08.06.2013
Santen Grants Rights to Subscribe for New Shares as Stock Options
05.08.2013
Name Change of European Subsidiary
05.08.2013
Santen to issue Stock Option to Directors as Stock-Linked Remuneration
05.08.2013
Notice Concerning Abolition of Retirement Benefit Program for Directors
05.08.2013
Notice of the Nomination for Members of the Board of Directors
04.26.2013
Discontinuance and Abolition of Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
03.11.2013
Notice of the appointment of Corporate Officers
01.25.2013
Santen announced the launch of Eternity Natural Uni and Accuject UniFit, a novel acrylic intraocular lens and its dedicated injector system
01.18.2013
Santen Announces Approval of TAPROS MINI Ophthalmic Solution 0.0015% for Glaucoma and Ocular Hypertension Treatment in Japan
News Archive
